[A23-140] Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V

Last updated 02.04.2024

Project no.:
A23-140

Commission:
Commission awarded on 21.12.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adults with relapsed or refractory diffuse large B-cell lymphoma

Result of dossier assessment:
  • after failure of one line of systemic therapy, for whom haematopoietic stem cell transplantation is not an option: added benefit not proven
  • after failure of ≥ 2 lines of systemic therapy, for whom CAR-T cell therapy is an option and for whom haematopoietic stem cell transplantation is not an option: added benefit not proven
  • after failure of ≥ 2 lines of systemic therapy, for whom CAR-T cell therapy and haematopoietic stem cell transplantation are not an option: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A23-140_en

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form